This is a review of the SPIRIT study, a head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis.
A total of 684 patients with PsA were recruited from 131 sites in 22 countries across North and South America, Australia, Europe, Asia and Africa. Commentary is provided by Associate Professor Andrew Östör, a Consultant Rheumatologist at Cabrini Medical Centre and Researcher at Emeritus Research, Melbourne.
Please login below to download this issue (PDF)